News Conference News THT 2023 High-Intensity Care After Acute HF Pays Off Across LVEF Spectrum: STRONG-HF Todd Neale March 23, 2023
News Conference News THT 2023 REDUCE LAP-HF II Subanalysis Makes the Case for Invasive Exercise Tests Yael L. Maxwell March 22, 2023
News Conference News ACC 2023 IMPLEMENT-HF: ‘Virtual’ Stewardship May Help Optimize GDMT in HFrEF L.A. McKeown March 14, 2023
News Conference News ACC 2023 How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA Todd Neale March 09, 2023
News Conference News ACC 2023 STELLAR, ‘Impressive’ Results With Novel Drug Sotatercept in PAH Shelley Wood March 06, 2023
News Conference News ACC 2023 BETTER CARE-HF: Embedded EHR Alert Boosts MRA Prescribing in HFrEF L.A. McKeown March 06, 2023
News Daily News Vast Majority of HFrEF Patients Eligible for Vericiguat L.A. McKeown February 08, 2023
News Conference News HFSA 2022 New Dapagliflozin Insights: Early Benefits and Types of Deaths Prevented Todd Neale October 07, 2022
News Conference News HFSA 2022 REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status L.A. McKeown October 07, 2022
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for June 2022 Caitlin E. Cox July 04, 2022
News Daily News ESC Heart Failure 2022 SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH Shelley Wood May 22, 2022
News Conference News ACC 2022 Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term Shelley Wood April 03, 2022
News Conference News THT 2022 Probe Beyond Ejection Fraction to Understand and Manage HFpEF L.A. McKeown February 07, 2022
News Conference News STS 2022 Modified Surgical MV Repair Stands Up to Replacement Michael O'Riordan February 03, 2022